Baxdrostat Shows Potential as Permanent Cure for Hormonal Hypertension
New research suggests a daily pill could replace surgery for specific blood pressure patients.
1Breakthrough in Hypertension Treatment
A new drug called baxdrostat, originally designed to manage blood pressure, shows potential as a permanent cure for specific patients. By inhibiting the hormone aldosterone, the medication addresses a common cause of hypertension. Researchers observed that the drug may eliminate benign adrenal gland tumours, offering a transformative alternative to chronic medication.
2Targeting Adrenal Gland Tumours
Approximately one in ten hypertension patients suffer from tiny benign tumours in their adrenal glands that overproduce aldosterone. Currently, these patients often require major surgery to remove the affected gland for a cure. Baxdrostat now presents a non-surgical pathway, potentially killing these hormone-producing cells through a daily oral pill regimen.
3Mechanism of Cellular Destruction
The drug functions by blocking aldosterone production, which inadvertently creates reactive oxygen species. These energetic compounds appear highly toxic to the tumour cells, effectively causing their death. Professor Morris Brown suggests this process allows for a finite course of medication to potentially provide an infinite cure for affected individuals.
4Clinical Trial Observations
In a study involving 14 patients, participants experienced an average systolic blood pressure reduction of 25 millimetres of mercury. After continuing the drug for six to 12 months and then stopping, their blood pressure remained low for up to two years. One patient has maintained these results for three years.
5Shifting From Chronic Care
The medical community is optimistic about moving from lifelong chronic treatment to a definitive cure. Professor Mason Freeman notes that this sustained remission could allow patients to achieve benefits previously reserved for invasive adrenal surgery. This shift represents a significant evolution in how clinicians approach hormonal hypertension and patient recovery.
6Regulatory Status and Availability
Baxdrostat received US approval this year for patients whose blood pressure remains dangerously high despite using two or more standard medications. In Britain, the National Institute for Health and Care Excellence is currently evaluating the drug for potential NHS availability next year, specifically targeting those with stubborn, treatment-resistant high blood pressure.
7Need for Further Validation
While initial findings are extraordinary, experts emphasize that larger studies are necessary to confirm these results. The current analysis stems from a follow-up of a larger trial originally intended to prove the drug's efficacy as a standard, long-term medication. Ongoing research will determine if a finite course provides permanent remission.
8Future Clinical Implications
If validated, this treatment could benefit over a million people in Britain alone, as nearly a third of adults suffer from high blood pressure. By replacing invasive procedures with a simple daily pill, the medical field may soon offer a more accessible, less traumatic solution for patients with hormonal hypertension.
Original article: iNews — Baxdrostat Shows Potential as Permanent Cure for Hormonal Hypertension